Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians

• Published in: Annals of internal medicine Vol. 177; no. 5; p. 658
• Main Authors: Qaseem, Amir, Obley, Adam J, Shamliyan, Tatyana, Hicks, Lauri A, Harrod, Curtis S, Crandall, Carolyn J, Balk, Ethan M, Cooney, Thomas G, Cross, Jr, J Thomas, Fitterman, Nick, Lin, Jennifer S, Maroto, Michael, Miller, Matthew C, Shekelle, Paul, Tice, Jeffrey A, Tufte, Janice E, Etxeandia-Ikobaltzeta, Itziar, Yost, Jennifer
• Format: Journal Article
• Language: English
• Published: United States 01.05.2024
• Subjects: Adult; Diabetes Mellitus, Type 2 - drug therapy; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Drug Therapy, Combination; Glucagon-Like Peptide 1 - agonists; Glucagon-Like Peptide 1 - therapeutic use; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Insulin - therapeutic use; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
• ISSN: 1539-3704
• DOI: 10.7326/M23-2788

The American College of Physicians (ACP) developed this clinical guideline to update recommendations on newer pharmacologic treatments of type 2 diabetes. This clinical guideline is based on the best available evidence for effectiveness, comparative benefits and harms, consideration of patients' values and preferences, and costs. This clinical guideline is based on a systematic review of the effectiveness and harms of newer pharmacologic treatments of type 2 diabetes, including glucagon-like peptide-1 (GLP-1) agonists, a GLP-1 agonist and glucose-dependent insulinotropic polypeptide agonist, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and long-acting insulins, used either as monotherapy or in combination with other medications. The Clinical Guidelines Committee prioritized the following outcomes, which were evaluated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach: all-cause mortality, major adverse cardiovascular events, myocardial infarction, stroke, hospitalization for congestive heart failure, progression of chronic kidney disease, serious adverse events, and severe hypoglycemia. Weight loss, as measured by percentage of participants who achieved at least 10% total body weight loss, was a prioritized outcome, but data were insufficient for network meta-analysis and were not rated with GRADE. The audience for this clinical guideline is physicians and other clinicians. The population is nonpregnant adults with type 2 diabetes.